{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:09:39Z","timestamp":1792462179889,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,17]]},"DOI":"10.7759\/cureus.58446","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T06:35:36Z","timestamp":1713335736000},"source":"Crossref","is-referenced-by-count":10,"title":["Polmacoxib: A Review of the Newer Non-steroidal Anti-inflammatory Drug in Osteoarthritis"],"prefix":"10.7759","author":[{"given":"Raju","family":"Easwaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi K","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Bhole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Peethambaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2011.01608.x","article-title":"The epidemiology of osteoarthritis in Asia","volume":"14","author":"Fransen M","year":"2011","unstructured":"Fransen M, Bridgett L, March L, Hoy D, Penserga E, Brooks P. The epidemiology of osteoarthritis in Asia. Int J Rheum Dis. 2011, 14:113-21. 10.1111\/j.1756-185X.2011.01608.x","journal-title":"Int J Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2022.05.004","article-title":"Burden of osteoarthritis in India and its states, 1990-2019: findings from the Global Burden of disease study 2019","volume":"30","author":"Singh A","year":"2022","unstructured":"Singh A, Das S, Chopra A, et al.. Burden of osteoarthritis in India and its states, 1990-2019: findings from the Global Burden of disease study 2019. Osteoarthr Cartil. 2022, 30:1070-8. 10.1016\/j.joca.2022.05.004","journal-title":"Osteoarthr Cartil"},{"key":"ref3","article-title":"Osteoarthritis","author":"Sen R","year":"2023","unstructured":"Sen R, Hurley JA. Osteoarthritis. StatPearls, Treasure Island, FL; 2023."},{"key":"ref4","article-title":"Nonsteroidal Anti-inflammatory Drugs (NSAIDs)","author":"Ghlichloo I","year":"2023","unstructured":"Ghlichloo I, Gerriets V. Nonsteroidal Anti-inflammatory Drugs (NSAIDs). StatPearls, Treasure Island, FL; 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2019.06.011","article-title":"OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis","volume":"27","author":"Bannuru RR","year":"2019","unstructured":"Bannuru RR, Osani MC, Vaysbrot EE, et al.. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019, 27:1578-89. 10.1016\/j.joca.2019.06.011","journal-title":"Osteoarthr Cartil"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00010","article-title":"Synthetic approaches to the new drugs approved during 2015","volume":"60","author":"Flick AC","year":"2017","unstructured":"Flick AC, Ding HX, Leverett CA, Kyne RE Jr, Liu KK, Fink SJ, O'Donnell CJ. Synthetic approaches to the new drugs approved during 2015. J Med Chem. 2017, 60:6480-515. 10.1021\/acs.jmedchem.7b00010","journal-title":"J Med Chem"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1063-4584(09)60346-0","article-title":"CG100649, a tissue-specific dual inhibitor of COX-2 and carbonic anhydrase: phase 2a clinical trial in hip & knee osteoarthritis","volume":"17","author":"Schmidt W","year":"2009","unstructured":"Schmidt W, Lehnhardt K, Hettwer J, et al.. CG100649, a tissue-specific dual inhibitor of COX-2 and carbonic anhydrase: phase 2a clinical trial in hip &amp; knee osteoarthritis. Osteoarthr Cartil. 2009, 17:10.1016\/S1063-4584(09)60346-0","journal-title":"Osteoarthr Cartil"},{"key":"ref8","unstructured":"Recommendations of the SEC (Analgesic &amp; Rheumatology) Made in Its 93rd Meeting Held on 14.02.2023 at CDSCO (HQ), New Delhi. https.\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/Recommendations%20Analgesic%20."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X210561","article-title":"Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization","volume":"23","author":"Sun SX","year":"2007","unstructured":"Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin. 2007, 23:1859-66. 10.1185\/030079907X210561","journal-title":"Curr Med Res Opin"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4055\/cios.2017.9.4.439","article-title":"A randomized, multicenter, phase III trial to evaluate the efficacy and safety of polmacoxib compared with celecoxib and placebo for patients with osteoarthritis","volume":"9","author":"Lee M","year":"2017","unstructured":"Lee M, Yoo J, Kim JG, et al.. A randomized, multicenter, phase III trial to evaluate the efficacy and safety of polmacoxib compared with celecoxib and placebo for patients with osteoarthritis. Clin Orthop Surg. 2017, 9:439-57. 10.4055\/cios.2017.9.4.439","journal-title":"Clin Orthop Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.11.008","article-title":"Population pharmacokinetic and pharmacodynamic analysis of polmacoxib in healthy volunteers and patients with osteoarthritis","volume":"44","author":"Cho YS","year":"2022","unstructured":"Cho YS, Bae KS, Choi SC, Cho JM, Lim HS. Population pharmacokinetic and pharmacodynamic analysis of polmacoxib in healthy volunteers and patients with osteoarthritis. Clin Ther. 2022, 44:67-80.e1. 10.1016\/j.clinthera.2021.11.008","journal-title":"Clin Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.07.007","article-title":"Pharmacokinetic, pharmacodynamic, and safety\/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women","volume":"37","author":"Kim MJ","year":"2015","unstructured":"Kim MJ, Lim HS, Jin S, Jung JA, Noh YH, Kim YH, Bae KS. Pharmacokinetic, pharmacodynamic, and safety\/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015, 37:197-210. 10.1016\/j.clinthera.2014.07.007","journal-title":"Clin Ther"},{"key":"ref13","unstructured":"National Center for Biotechnology Information. PubChem Substance Record for SID 173334219, Polmacoxib [USAN.INN], Source: ChemIDplus. https:\/\/pubchem.ncbi.nlm.nih.gov\/substance\/173334219."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.3","article-title":"Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649","volume":"91","author":"Skarke C","year":"2012","unstructured":"Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther. 2012, 91:986-93. 10.1038\/clpt.2012.3","journal-title":"Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.47","article-title":"GCG100649, A novel cyclooxygenase-2 inhibitor, exhibits a drug disposition profile in healthy volunteers compatible with high affinity to carbonic anhydrase-I\/II: Preliminary dose-exposure relationships to define clinical development strategies","volume":"2","author":"Hirankarn S","year":"2013","unstructured":"Hirankarn S, Barrett JS, Alamuddin N, FitzGerald GA, Skarke C. GCG100649, A novel cyclooxygenase-2 inhibitor, exhibits a drug disposition profile in healthy volunteers compatible with high affinity to carbonic anhydrase-I\/II: Preliminary dose-exposure relationships to define clinical development strategies. Clin Pharmacol Drug Dev. 2013, 2:379-86. 10.1002\/cpdd.47","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/229040-polmacoxib-a-review-of-the-newer-non-steroidal-anti-inflammatory-drug-in-osteoarthritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T06:35:40Z","timestamp":1713335740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/229040-polmacoxib-a-review-of-the-newer-non-steroidal-anti-inflammatory-drug-in-osteoarthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.58446","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,17]]}}}